The acquisition of SoniVie Ltd by Boston Scientific is likely to positively impact BSX's stock price in the short term. This strategic move expands their product offerings in the Interventional Cardiology Therapies sector, specifically targeting hypertension treatment. Such expansions are generally viewed favorably by investors as they can lead to increased market share and revenue growth.